Semathera Inc.

SemaThera (www.semathera.com) is a biotech company spun out from our semaphorin 3A (“SEMA 3A”) program led by Dr. Mike (Przemyslaw) Sapieha from the Université de Montréal and Maisonneuve-Rosemont Hospital. SemaThera is focusing on the development of novel anti-SEMA 3A therapies for the treatment of several retinopathies, including diabetic macular edema and the wet form of age-related macular degeneration . SemaThera also holds exclusive rights to various SEMA 3A-based technologies, where the target is involved in neo-angiogenesis, senescence and neuronal regeneration. Such technologies may also become tomorrow’s treatments in cancer and neurodegenerative diseases.